Press Releases

Date Title and Summary View
Toggle Summary Revance Releases Fourth Quarter and Full Year 2018 Results
-Successful 2018: Positive SAKURA 3 topline data, Fosun and Mylan partnerships signed- -On track to complete BLA submission with U.S. FDA for glabellar lines indication in the first half of 2019- -Raised approximately $108 million net proceeds from public stock offering on January 22, 2019 -
View HTML
Toggle Summary Revance to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019
Conference Call Scheduled for Tuesday, February 26, 2019 at 4:30pm ET NEWARK, Calif. --(BUSINESS WIRE)--Feb. 12, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today
View HTML
Toggle Summary Revance Announces Closing of Public Offering of Common Stock
Gross Proceeds of Offering Total 115.0 Million NEWARK, Calif. --(BUSINESS WIRE)--Jan. 22, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today
View HTML
Toggle Summary Revance Announces Pricing of Public Offering of Common Stock
NEWARK, Calif. --(BUSINESS WIRE)--Jan. 17, 2019-- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced the pricing of an underwritten public
View HTML
Toggle Summary Revance Announces Proposed Public Offering of Common Stock
NEWARK, Calif. --(BUSINESS WIRE)--Jan. 15, 2019-- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced a proposed underwritten public
View HTML
Toggle Summary Revance Announces Ground-Breaking Data Presentations at Leading International Neurotoxin Conference
- Revance’s long-acting neuromodulator RT002, along with its unique proprietary peptide and formulation technology, will be featured in 11 podium and poster presentations at the TOXINS 2019 conference in Denmark - NEWARK, Calif. --(BUSINESS WIRE)--Jan. 15, 2019-- Revance Therapeutics, Inc.
View HTML
Toggle Summary Revance Highlights Recent Regulatory Progress and Provides Anticipated 2019 Milestones
- Completes Type B Pre-BLA meeting with U.S. FDA for glabellar lines indication and remains on track to submit application in first half of 2019 - - Initiates Phase 2 trials for RT002 in both plantar fasciitis and adult upper limb spasticity - NEWARK, Calif. --(BUSINESS WIRE)--Jan.
View HTML
Toggle Summary Revance Announces China Market License Agreement with Fosun Pharma for RT002
– Upfront payment of $30 million , plus potential milestone payment and tiered royalties on future sales – NEWARK, Calif. --(BUSINESS WIRE)--Dec. 4, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and
View HTML
Toggle Summary Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program
– In SAKURA 3, RT002 was well-tolerated across over 3,800 treatments in glabellar (frown) lines – – The median time to return to baseline glabellar line severity was 28 weeks – – RT002 represents the first long-acting neuromodulator, allowing for two or fewer treatments per year – – Revance
View HTML
Toggle Summary Revance to Participate in Upcoming Investor Conferences
NEWARK, Calif. --(BUSINESS WIRE)--Nov. 20, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor
View HTML
Shareholder Tools Request Printed Materials Request Email Alerts Download Library RSS News Feeds Share this Page Search Investor Site
Shareholder Tools